PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript March 27, 2024 PDS Biotechnology Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. And welcome to PDS Biotech’s call to discuss the company’s Year-End 2023 Financial Results and […]
PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
08.08.2022 - Announced results from two of the ongoing Phase 2 clinical trials of PDS0101 in multiple, difficult-to-treat HPV16-related cancers presented at the American Society of Clinical Oncology meetingPromising pre-clinical data on universal flu vaccine .